Table 2.
Summary of safety data
| Older cohort (n = 70) | Younger cohort (n = 70) | P value | |
|---|---|---|---|
| irAEs incidence | |||
| irAEs any grade, n (%) | 42 (60.0) | 36 (51.4) | 0.395 |
| irAEs grade 3-5, n (%) | 13 (18.6) | 9 (12.9) | 0.353 |
| Toxic death, n (%) | 1 (1.4) | 0 (0.0) | 0.999 |
| CPI discontinuation (toxicity related) | |||
| n (%) | 13 (18.6) | 10 (14.3) | 0.494 |
| Immunosuppressants use (PO/IV) | |||
| Steroids, n (%) | 20 (28.6) | 17 (24.3) | 0.565 |
| Median duration, weeks (range) | 22 (1-32) | 8 (1-52) | 0.208 |
| Infliximab, n (%) | 1 (1.4) | 1 (1.4) | 0.999 |
| Mycophenolate, n (%) | 2 (2.9) | 2 (2.9) | 0.999 |
| AEs incidence | |||
| AEs grade 3-5, n (%) | 19 (27.1) | 16 (22.9) | 0.558 |
| Hospital admission | |||
| n (%) | 34 (48.6) | 35 (50.0) | 0.866 |
| Hospital admission causes | |||
| irAE related, n (%) | 14 (20.0) | 10 (14.3) | 0.369 |
| Other causes, n (%) | 27 (38.6) | 25 (35.7) | 0.726 |
| Hospital hotline use | |||
| n (%) | 44 (62.9) | 35 (50.0) | 0.125 |
CPI, checkpoint inhibitor; irAEs, immune-related adverse events; IV, intravenous; PO, per os.